Cargando…

Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma

INTRODUCTION: Lysophosphatidic acid (LPA) is a bioactive phospholipid with diverse effects on various cells. It interacts with at least three G-protein-coupled transmembrane receptors, namely LPA1, LPA2 and LPA3, whose expression in various tumours has not been fully characterized. In the present st...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitayama, Joji, Shida, Dai, Sako, Akihiro, Ishikawa, Makoto, Hama, Kotaro, Aoki, Junken, Arai, Hiroyuki, Nagawa, Hirokazu
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064082/
https://www.ncbi.nlm.nih.gov/pubmed/15535846
http://dx.doi.org/10.1186/bcr935
_version_ 1782123285062877184
author Kitayama, Joji
Shida, Dai
Sako, Akihiro
Ishikawa, Makoto
Hama, Kotaro
Aoki, Junken
Arai, Hiroyuki
Nagawa, Hirokazu
author_facet Kitayama, Joji
Shida, Dai
Sako, Akihiro
Ishikawa, Makoto
Hama, Kotaro
Aoki, Junken
Arai, Hiroyuki
Nagawa, Hirokazu
author_sort Kitayama, Joji
collection PubMed
description INTRODUCTION: Lysophosphatidic acid (LPA) is a bioactive phospholipid with diverse effects on various cells. It interacts with at least three G-protein-coupled transmembrane receptors, namely LPA1, LPA2 and LPA3, whose expression in various tumours has not been fully characterized. In the present study we characterized the expression profile of LPA receptors in human breast cancer tissue and assessed the possible roles of each receptor. METHODS: The relative expression levels of each receptor's mRNA against β-actin mRNA was examined in surgically resected invasive ductal carcinomas and normal gland tissue using real-time RT-PCR. LPA2 expression was also examined immunohistochemically using a rat anti-LPA2 monoclonal antibody. RESULTS: In 25 cases normal and cancer tissue contained LPA1 mRNA at similar levels, whereas the expression level of LPA2 mRNA was significantly increased in cancer tissue as compared with its normal counterpart (3479.0 ± 426.6 versus 1287.3 ± 466.8; P < 0.05). LPA3 was weakly expressed in both cancer and normal gland tissue. In 48 (57%) out of 84 cases, enhanced expression of LPA2 protein was confirmed in carcinoma cells as compared with normal mammary epithelium by immunohistochemistry. Over-expression of LPA2 was detected in 17 (45%) out of 38 premenopausal women, as compared with 31 (67%) out of 46 postmenopausal women, and the difference was statistically significant (P < 0.05). CONCLUSION: These findings suggest that upregulation of LPA2 may play a role in carcinogenesis, particularly in postmenopausal breast cancer.
format Text
id pubmed-1064082
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10640822005-03-11 Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma Kitayama, Joji Shida, Dai Sako, Akihiro Ishikawa, Makoto Hama, Kotaro Aoki, Junken Arai, Hiroyuki Nagawa, Hirokazu Breast Cancer Res Research Article INTRODUCTION: Lysophosphatidic acid (LPA) is a bioactive phospholipid with diverse effects on various cells. It interacts with at least three G-protein-coupled transmembrane receptors, namely LPA1, LPA2 and LPA3, whose expression in various tumours has not been fully characterized. In the present study we characterized the expression profile of LPA receptors in human breast cancer tissue and assessed the possible roles of each receptor. METHODS: The relative expression levels of each receptor's mRNA against β-actin mRNA was examined in surgically resected invasive ductal carcinomas and normal gland tissue using real-time RT-PCR. LPA2 expression was also examined immunohistochemically using a rat anti-LPA2 monoclonal antibody. RESULTS: In 25 cases normal and cancer tissue contained LPA1 mRNA at similar levels, whereas the expression level of LPA2 mRNA was significantly increased in cancer tissue as compared with its normal counterpart (3479.0 ± 426.6 versus 1287.3 ± 466.8; P < 0.05). LPA3 was weakly expressed in both cancer and normal gland tissue. In 48 (57%) out of 84 cases, enhanced expression of LPA2 protein was confirmed in carcinoma cells as compared with normal mammary epithelium by immunohistochemistry. Over-expression of LPA2 was detected in 17 (45%) out of 38 premenopausal women, as compared with 31 (67%) out of 46 postmenopausal women, and the difference was statistically significant (P < 0.05). CONCLUSION: These findings suggest that upregulation of LPA2 may play a role in carcinogenesis, particularly in postmenopausal breast cancer. BioMed Central 2004 2004-09-22 /pmc/articles/PMC1064082/ /pubmed/15535846 http://dx.doi.org/10.1186/bcr935 Text en Copyright © 2004 Kitayama et al., licensee BioMed Central Ltd.
spellingShingle Research Article
Kitayama, Joji
Shida, Dai
Sako, Akihiro
Ishikawa, Makoto
Hama, Kotaro
Aoki, Junken
Arai, Hiroyuki
Nagawa, Hirokazu
Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma
title Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma
title_full Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma
title_fullStr Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma
title_full_unstemmed Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma
title_short Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma
title_sort over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064082/
https://www.ncbi.nlm.nih.gov/pubmed/15535846
http://dx.doi.org/10.1186/bcr935
work_keys_str_mv AT kitayamajoji overexpressionoflysophosphatidicacidreceptor2inhumaninvasiveductalcarcinoma
AT shidadai overexpressionoflysophosphatidicacidreceptor2inhumaninvasiveductalcarcinoma
AT sakoakihiro overexpressionoflysophosphatidicacidreceptor2inhumaninvasiveductalcarcinoma
AT ishikawamakoto overexpressionoflysophosphatidicacidreceptor2inhumaninvasiveductalcarcinoma
AT hamakotaro overexpressionoflysophosphatidicacidreceptor2inhumaninvasiveductalcarcinoma
AT aokijunken overexpressionoflysophosphatidicacidreceptor2inhumaninvasiveductalcarcinoma
AT araihiroyuki overexpressionoflysophosphatidicacidreceptor2inhumaninvasiveductalcarcinoma
AT nagawahirokazu overexpressionoflysophosphatidicacidreceptor2inhumaninvasiveductalcarcinoma